OKYO Pharma Limited Sponsored ADR (OKYO) Price & Analysis

Compare

116 Followers

OKYO Stock Chart & Stats

$1.66

$0.09(7.75%)

At close: Jan 08 4:00 PM EST

$1.66

$0.09(7.75%)

Day’s Range― - ―

52-Week Range$1.03 - $3.35

Previous CloseN/A

Volume700.83K

Average Volume (3M)131.52K

Market Cap

$86.82M

Enterprise Value$64.50M

Total Cash (Recent Filing)$4.22M

Total Debt (Recent Filing)$185.79K

Price to Earnings (P/E)―

Beta0.36

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding51,370,197

10 Day Avg. Volume47,624

30 Day Avg. Volume131,524

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)-9.04

Price to Sales (P/S)0.00

P/FCF Ratio-27.67

Enterprise Value/Market Cap0.74

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-29.67K

Enterprise Value/Ebitda-6.73

Forecast

1Y Price Target

$6.33

Price Target Upside281.33% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical EfficacyPhase 2 results showed a statistically significant reduction in pain for patients treated with 0.05% urcosimod and higher responder rates versus placebo, supporting potential for meaningful clinical benefit in neuropathic corneal pain.

Mechanism And Potential Disease ModificationUrcosimod's dual action on inflammatory and neuronal pathways, together with directional improvements in corneal nerve structure observed in analyses, suggests potential for corneal nerve restoration and a differentiated therapeutic profile.

Regulatory EndorsementFDA alignment on the visual analogue scale as a clinically meaningful endpoint, acceptance of the proposed study design and supportive quality-of-life measures, and agreement on CMC strategy reduce regulatory uncertainty for pivotal development.

Bears Say

Data RobustnessCorneal image findings come from a small exploratory analysis and require confirmation in larger, well-powered trials, leaving uncertainty about whether the structural improvements will be replicated.

Program Risk ProfileThe program faces multiple risks across clinical, regulatory, commercial, financing, and intellectual property fronts that could delay progress or constrain future market opportunities.

OKYO Pharma Limited Sponsored ADR News

Okyo Pharma initiated with an Overweight at Piper Sandler

Piper Sandler analyst Biren Amin initiated coverage of Okyo Pharma (OKYO) with an Overweight rating and $7 price...

14d ago

OKYO

Okyo Pharma $20M Spot Secondary; price range $1.80-$1.90

Piper Sandler is acting as sole book running manager for the offering. Published first on TheFly – the...

22d ago

OKYO

Okyo Pharma announces ordinary shares offering, no amount given

Okyo Pharma (OKYO) Limited announced that it intends to offer to sell its ordinary shares in an underwritten...

22d ago

OKYO

Okyo Pharma appoints Mantelli as Chief Medical Officer

OKYO Pharma (OKYO) announced the appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer. Dr. Mantelli led...

24d ago

OKYO

OKYO Pharma’s Urcosimod NCP Data Selected for Presentation at ARVO 2026

OKYO Pharma Limited Sponsored ADR ( ($OKYO) ) has shared an update. On February 23, 2026, OKYO Pharma...

11d ago

OKYO

OKYO Pharma Prices $20 Million Underwritten Share Offering to Fund Clinical Development

OKYO Pharma Limited Sponsored ADR ( ($OKYO) ) just unveiled an announcement. On February 12, 2026, OKYO Pharma...

21d ago

OKYO

OKYO Pharma Prices $20 Million Public Share Offering to Fund Eye Disease Pipeline

OKYO Pharma Limited Sponsored ADR ( ($OKYO) ) has provided an announcement. On February 12, 2026, OKYO Pharma...

21d ago

OKYO

OKYO Pharma Launches Public Offering to Fund Next Phase of Corneal Pain Drug Development

The latest announcement is out from OKYO Pharma Limited Sponsored ADR ( ($OKYO) ). On February 12, 2026,...

22d ago

OKYO

OKYO Pharma Switches ATM Equity Facility to Leerink Partners to Support Urcosimod Push

OKYO Pharma Limited Sponsored ADR ( ($OKYO) ) has provided an announcement. On February 11, 2026, OKYO Pharma...

23d ago

OKYO

OKYO Pharma Launches $50 Million At-the-Market Share Offering With Leerink Partners

OKYO Pharma Limited Sponsored ADR ( ($OKYO) ) has shared an announcement. On February 10, 2026, OKYO Pharma...

23d ago

OKYO

OKYO Pharma Hires Oxervate Veteran Flavio Mantelli as Chief Medical Officer to Drive Urcosimod Program

OKYO Pharma Limited Sponsored ADR ( ($OKYO) ) has issued an update. OKYO Pharma announced on February 10,...

24d ago

OKYO

OKYO Pharma Advances Urcosimod With Positive Interim Results and FDA Alignment on Phase 2b/3 NCP Trial

An announcement from OKYO Pharma Limited Sponsored ADR ( ($OKYO) ) is now available. On January 30, 2026,...

1M ago

OKYO

OKYO Pharma’s Urcosimod Phase 2 Data Accepted for Presentation at 2026 ASCRS Meeting

OKYO Pharma Limited Sponsored ADR ( ($OKYO) ) has issued an update. On January 30, 2026, OKYO Pharma...

1M ago

OKYO

OKYO Pharma Wins FDA Backing on Phase 2b/3 Design for Urcosimod in Neuropathic Corneal Pain

OKYO Pharma Limited Sponsored ADR ( ($OKYO) ) has issued an announcement. On January 28, 2026, OKYO Pharma...

1M ago

OKYO

OKYO FAQ

What was OKYO Pharma Limited Sponsored ADR’s price range in the past 12 months?

OKYO Pharma Limited Sponsored ADR lowest stock price was $1.03 and its highest was $3.35 in the past 12 months.

What is OKYO Pharma Limited Sponsored ADR’s market cap?

OKYO Pharma Limited Sponsored ADR’s market cap is $86.82M.

When is OKYO Pharma Limited Sponsored ADR’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were OKYO Pharma Limited Sponsored ADR’s earnings last quarter?

Currently, no data Available

Is OKYO Pharma Limited Sponsored ADR overvalued?

According to Wall Street analysts OKYO Pharma Limited Sponsored ADR’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does OKYO Pharma Limited Sponsored ADR pay dividends?

OKYO Pharma Limited Sponsored ADR does not currently pay dividends.

What is OKYO Pharma Limited Sponsored ADR’s EPS estimate?

OKYO Pharma Limited Sponsored ADR’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does OKYO Pharma Limited Sponsored ADR have?

OKYO Pharma Limited Sponsored ADR has 51,370,197 shares outstanding.

What happened to OKYO Pharma Limited Sponsored ADR’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of OKYO Pharma Limited Sponsored ADR?

Currently, no hedge funds are holding shares in OKYO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

OKYO Pharma Limited Sponsored ADR Stock Smart Score

Neutral

Company Description

OKYO Pharma Limited Sponsored ADR

OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.

OKYO Pharma Limited Sponsored ADR (OKYO) Earnings & Revenues

Historic Earnings Reports

OKYO Stock 12 Month Forecast

Average Price Target

$6.33

▲(281.33% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","2":"$2","4":"$4","6":"$6","8":"$8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2,4,6,8],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.77,2.1723076923076925,2.5746153846153845,2.976923076923077,3.3792307692307695,3.781538461538462,4.183846153846154,4.586153846153847,4.988461538461539,5.390769230769232,5.793076923076924,6.195384615384617,6.5976923076923075,{"y":7,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.77,2.120769230769231,2.4715384615384615,2.8223076923076924,3.1730769230769234,3.5238461538461543,3.874615384615385,4.225384615384616,4.576153846153847,4.926923076923078,5.277692307692309,5.628461538461539,5.979230769230769,{"y":6.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.77,2.0184615384615383,2.266923076923077,2.5153846153846153,2.7638461538461536,3.0123076923076924,3.2607692307692306,3.5092307692307694,3.7576923076923077,4.006153846153846,4.254615384615384,4.503076923076923,4.751538461538461,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.04,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.15,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.06,"date":1738368000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.26,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.18,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.56,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.61,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.32,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.86,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.07,"date":1767225600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.09,"date":1769904000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 75, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 19</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.77,"date":1772323200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 75, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 19</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >